Dr. Jay Amin (BM.PhD), Associate Professor in Psychiatry of Older Age, University of Southampton, Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, United Kingdom, Phone: 02380475206, Email:
J Prev Alzheimers Dis. 2023;10(2):276-286. doi: 10.14283/jpad.2023.20.
Imbalances in thyroid hormones have been linked with Alzheimer's dementia. Several studies have reported an association between thyroid disorders, such as hyper- or hypothyroidism, with Alzheimer's disease. However, there remains no consensus about the precise role of thyroid dysfunction in Alzheimer's disease. In this study we systematically searched PubMed, Embase and Scopus for clinical studies which reported the prevalence of hyper- or hypothyroidism in people with Alzheimer's disease compared to controls. Meta-analysis was performed to compare thyroid disorder prevalence in Alzheimer's disease and controls. Subgroup analysis was performed to assess the clinical and subclinical thyroid dysfunction, separately. Seven studies, including 1189 people with Alzheimer's disease and 72711 controls, were included in our sample. Hypothyroidism was significantly more prevalent in Alzheimer's disease compared with controls (6.4% vs 2.4%, p=0.01). Subgroup analysis showed that clinical hypothyroidism was not significantly different between Alzheimer's disease compared to controls (10.0% vs 5.3%, p=0.35). There was no difference in the crude overall prevalence of clinical and subclinical hyperthyroidism in Alzheimer's disease versus controls (2.4 vs 1.9%, p=0.73). Our analyses revealed a higher prevalence of hypothyroidism in Alzheimer's disease. Whether this finding is explained by hypothyroidism being a risk factor for, or consequence of, Alzheimer's disease requires longitudinal analysis. Our review supports further work into a potential role for treatment of hypothyroidism in the prevention or delay of Alzheimer's disease.
甲状腺激素失衡与阿尔茨海默病有关。一些研究报告称,甲状腺疾病(如甲状腺功能亢进或减退症)与阿尔茨海默病之间存在关联。然而,关于甲状腺功能障碍在阿尔茨海默病中的确切作用,仍未达成共识。在这项研究中,我们系统地检索了 PubMed、Embase 和 Scopus,以寻找报告阿尔茨海默病患者中甲状腺功能亢进或减退症患病率与对照组相比的临床研究。进行了荟萃分析以比较阿尔茨海默病和对照组中甲状腺疾病的患病率。进行了亚组分析,以分别评估临床和亚临床甲状腺功能减退症。共有 7 项研究,包括 1189 名阿尔茨海默病患者和 72711 名对照者,纳入了我们的样本。与对照组相比,甲状腺功能减退症在阿尔茨海默病患者中更为常见(6.4%比 2.4%,p=0.01)。亚组分析显示,临床甲状腺功能减退症在阿尔茨海默病患者与对照组之间无显著差异(10.0%比 5.3%,p=0.35)。阿尔茨海默病患者与对照组的临床和亚临床甲状腺功能亢进症的总患病率在粗率上无差异(2.4%比 1.9%,p=0.73)。我们的分析显示,甲状腺功能减退症在阿尔茨海默病中更为常见。这种发现是否可以用甲状腺功能减退症是阿尔茨海默病的危险因素或后果来解释,需要进行纵向分析。我们的综述支持进一步研究治疗甲状腺功能减退症在预防或延缓阿尔茨海默病中的潜在作用。